169 related articles for article (PubMed ID: 36895986)
1. Prediction model of hepatocellular carcinoma in patients with hepatitis B virus-related compensated cirrhosis receiving antiviral therapy.
Wang HW; Chen CY; Lai HC; Hu TH; Su WP; Lu SN; Hung CH; Chuang PH; Wang JH; Chen CH; Peng CY
Am J Cancer Res; 2023; 13(2):526-537. PubMed ID: 36895986
[TBL] [Abstract][Full Text] [Related]
2. Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B.
Papatheodoridis GV; Dalekos GN; Idilman R; Sypsa V; Van Boemmel F; Buti M; Calleja JL; Goulis J; Manolakopoulos S; Loglio A; Papatheodoridi M; Gatselis N; Veelken R; Lopez-Gomez M; Hansen BE; Savvidou S; Kourikou A; Vlachogiannakos J; Galanis K; Yurdaydin C; Esteban R; Janssen HLA; Berg T; Lampertico P
JHEP Rep; 2021 Jun; 3(3):100290. PubMed ID: 34041470
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for hepatocellular carcinoma at baseline and 1 year after initiation of nucleos(t)ide analog therapy for chronic hepatitis B.
Kaneko S; Kurosaki M; Mashiba T; Marusawa H; Kondo M; Kojima Y; Uchida Y; Fujii H; Akahane T; Yagisawa H; Kusakabe A; Kobashi H; Abe T; Yoshida H; Ogawa C; Furuta K; Tamaki N; Tsuji K; Matsushita T; Izumi N;
J Med Virol; 2023 Jan; 95(1):e28210. PubMed ID: 36222204
[TBL] [Abstract][Full Text] [Related]
4. External Validation of aMAP Hepatocellular Carcinoma Risk Score in Patients With Chronic Hepatitis B-Related Cirrhosis Receiving ETV or TDF Therapy.
Gui H; Huang Y; Zhao G; Chen L; Cai W; Wang H; Guo Q; Xie Q
Front Med (Lausanne); 2021; 8():677920. PubMed ID: 34422855
[No Abstract] [Full Text] [Related]
5. Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy.
Kim JH; Kim YD; Lee M; Jun BG; Kim TS; Suk KT; Kang SH; Kim MY; Cheon GJ; Kim DJ; Baik SK; Choi DH
J Hepatol; 2018 Nov; 69(5):1066-1073. PubMed ID: 30075230
[TBL] [Abstract][Full Text] [Related]
6. Predicting the risk of hepatocellular carcinoma in chronic hepatitis B patients receiving antiviral therapy: Validating the CAMD and AASL scores in China.
Wang S; Liu B; Fan X; Gao Y; Hong M; Xu Y
Saudi J Gastroenterol; 2022; 28(5):362-368. PubMed ID: 35170433
[TBL] [Abstract][Full Text] [Related]
7. Validation of the HCC-RESCUE score to predict hepatocellular carcinoma risk in Caucasian chronic hepatitis B patients under entecavir or tenofovir therapy.
Güzelbulut F; Gökçen P; Can G; Adalı G; Değirmenci Saltürk AG; Bahadır Ö; Özdil K; Doğanay HL
J Viral Hepat; 2021 May; 28(5):826-836. PubMed ID: 33586270
[TBL] [Abstract][Full Text] [Related]
8. One-year Fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment.
Tseng TC; Choi J; Nguyen MH; Peng CY; Siakavellas S; Papatheodoridis G; Wang CC; Lim YS; Lai HC; Trinh HN; Wong C; Wong C; Zhang J; Li J; Kao JH
Hepatol Int; 2021 Feb; 15(1):105-113. PubMed ID: 33547557
[TBL] [Abstract][Full Text] [Related]
9. Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir.
Chang JW; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Seo YS; Lee HA; Kim MN; Lee YR; Hwang SG; Rim KS; Um SH; Tak WY; Kweon YO; Park SY; Kim SU
J Viral Hepat; 2021 Jan; 28(1):95-104. PubMed ID: 33029863
[TBL] [Abstract][Full Text] [Related]
10. Comparative performance of risk prediction models for hepatitis B-related hepatocellular carcinoma in the United States.
Kim HS; Yu X; Kramer J; Thrift AP; Richardson P; Hsu YC; Flores A; El-Serag HB; Kanwal F
J Hepatol; 2022 Feb; 76(2):294-301. PubMed ID: 34563579
[TBL] [Abstract][Full Text] [Related]
11. Stratification of hepatocellular carcinoma risk through modified FIB-4 index in chronic hepatitis B patients on entecavir therapy.
Wang HW; Lai HC; Hu TH; Su WP; Lu SN; Lin CH; Hung CH; Chuang PH; Wang JH; Lee MH; Chen CH; Peng CY
J Gastroenterol Hepatol; 2019 Feb; 34(2):442-449. PubMed ID: 29968933
[TBL] [Abstract][Full Text] [Related]
12. Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B.
Hsu YC; Yip TC; Ho HJ; Wong VW; Huang YT; El-Serag HB; Lee TY; Wu MS; Lin JT; Wong GL; Wu CY
J Hepatol; 2018 Aug; 69(2):278-285. PubMed ID: 29551708
[TBL] [Abstract][Full Text] [Related]
13. Deep learning model for prediction of hepatocellular carcinoma in patients with HBV-related cirrhosis on antiviral therapy.
Nam JY; Sinn DH; Bae J; Jang ES; Kim JW; Jeong SH
JHEP Rep; 2020 Dec; 2(6):100175. PubMed ID: 33117971
[TBL] [Abstract][Full Text] [Related]
14. Incidence and predictors of hepatocellular carcinoma beyond year 5 of entecavir therapy in chronic hepatitis B patients.
Sou FM; Hu TH; Hung CH; Lai HC; Wang JH; Lu SN; Peng CY; Chen CH
Hepatol Int; 2020 Jul; 14(4):513-520. PubMed ID: 32319045
[TBL] [Abstract][Full Text] [Related]
15. Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B.
Yip TC; Wong GL; Wong VW; Tse YK; Liang LY; Hui VW; Lee HW; Lui GC; Chan HL
J Hepatol; 2020 May; 72(5):847-854. PubMed ID: 31857194
[TBL] [Abstract][Full Text] [Related]
16. Impact of FIB-4 index on hepatocellular carcinoma incidence during nucleos(t)ide analogue therapy in patients with chronic hepatitis B: An analysis using time-dependent receiver operating characteristic.
Tada T; Kumada T; Toyoda H; Tsuji K; Hiraoka A; Tanaka J
J Gastroenterol Hepatol; 2017 Feb; 32(2):451-458. PubMed ID: 27288655
[TBL] [Abstract][Full Text] [Related]
17. Predictive score for hepatocellular carcinoma after hepatitis B e antigen loss in patients treated with entecavir or tenofovir.
Lim TS; Lee HW; Lee JI; Kim IH; Lee CH; Jang BK; Chung WJ; Yim HJ; Suh SJ; Seo YS; Lee HA; Yu JH; Lee JW; Kim SG; Kim YS; Park SY; Tak WY; Kim SS; Cheong JY; Jeong SW; Jang JY; Rou WS; Lee BS; Kim SU;
J Viral Hepat; 2020 Oct; 27(10):1052-1060. PubMed ID: 32383246
[TBL] [Abstract][Full Text] [Related]
18. A new model predicts hepatocellular carcinoma in patients with HBV-related decompensated liver cirrhosis and long-term antiviral therapy: a prospective study.
Mao HD; Zheng SQ; Yang SH; Huang ZY; Xue Y; Zhou M
PeerJ; 2023; 11():e15014. PubMed ID: 36992940
[TBL] [Abstract][Full Text] [Related]
19. On-Treatment Changes in FIB-4 and 1-Year FIB-4 Values Help Identify Patients with Chronic Hepatitis B Receiving Entecavir Therapy Who Have the Lowest Risk of Hepatocellular Carcinoma.
Wang HW; Lai HC; Hu TH; Su WP; Lu SN; Lin CH; Hung CH; Chuang PH; Wang JH; Lee MH; Chen CH; Peng CY
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32392752
[TBL] [Abstract][Full Text] [Related]
20. Prediction model for hepatocellular carcinoma risk in treatment-naive chronic hepatitis B patients receiving entecavir/tenofovir.
Yu JH; Suh YJ; Jin YJ; Heo NY; Jang JW; You CR; An HY; Lee JW
Eur J Gastroenterol Hepatol; 2019 Jul; 31(7):865-872. PubMed ID: 30694912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
